Author name: Leonardo Arias

The ruling removes a barrier to a deal the FTC claims will eliminate competition in the outsourced hydrophilic coatings market.

Major payers with a presence in the ACA, Medicare or Medicaid posted an average operating margin of -1.4% in the third quarter. The market “continues to be challenging,” complicating margin recovery plans, one expert said.

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of the “lingering uncertainties” surrounding the FDA, wrote one industry analyst.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The company also posted weaker third-quarter results, but CEO David Fischel said orders for the new GenesisX system, when fully launched, would outpace the rate for an older model.

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.

C-suite executives surveyed said they think new technology leadership roles will become more important in the next three years, according to a report from the Healthcare Financial Management Association.

The lowest level of quarterly VC funding since 2023 has tempered expectations that the sector will achieve its best year since 2021.

The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company expects to generate initial Phase I data for its lead asset MGX-001 in hemophilia A.

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.